Diclofenac (systemic): Drug information

(For additional information see "Diclofenac (systemic): Patient drug information" and see "Diclofenac (systemic): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)

ALERT: US Boxed Warning

Serious cardiovascular thrombotic events:

Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.

Diclofenac is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Serious gastrointestinal bleeding, ulceration, and perforation:

NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

Brand Names: US

Cambia;
Cataflam [DSC];
Lofena;
Zipsor;
Zorvolex [DSC]

Brand Names: Canada

APO-Diclo;
APO-Diclo SR;
Cambia;
Diclofenac-50;
PMS-Diclofenac;
PMS-Diclofenac K [DSC];
PMS-Diclofenac-SR [DSC];
PRO-Diclo Rapide-50 [DSC];
SANDOZ Diclofenac;
SANDOZ Diclofenac Rapide;
SANDOZ Diclofenac SR;
TEVA-Diclofenac EC;
TEVA-Diclofenac SR;
TEVA-Diclofenac-K;
Voltaren;
Voltaren Rapide;
Voltaren SR

Pharmacologic Category

Analgesic, Nonopioid;
Nonsteroidal Anti-inflammatory Drug (NSAID);
Nonsteroidal Anti-inflammatory Drug (NSAID), Oral

Dosing: Adult

Dosage guidance:

Safety: Avoid or use with caution in patients at risk for cardiovascular disease, GI disease, kidney impairment, chronic liver disease, or a bleeding diathesis. Consider proton pump inhibitor coadministration in patients at risk for GI bleeding (eg, taking dual antiplatelet therapy or an anticoagulant, ≥60 years of age, high diclofenac doses) (Ref).

Dosing: Use the lowest effective dose for the shortest duration. For diclofenac potassium and sodium salt formulations, the US maximum daily dose is 150 to 200 mg/day; however, Health Canada recommends not exceeding 100 mg/day to limit risk of vascular events (Ref). Diclofenac acid maximum dose is 105 mg/day.

Dosage form information: Diclofenac potassium and sodium salt formulations are approximately equivalent and dosed the same. Diclofenac acid 35 mg is approximately equivalent to diclofenac salts 38.5 mg.

Acute pain

Acute pain (monotherapy or as adjunctive agent):

Oral: Diclofenac potassium or sodium formulations: 100 to 150 mg/day in divided doses as needed or scheduled (may choose immediate release [given in 2 to 4 divided doses], delayed release [given in 2 to 4 divided doses], or extended release [given once daily]); may administer 100 mg as an initial loading dose followed by a maintenance dose; maximum dose (after day 1): 150 mg/day (Ref).

Oral: Diclofenac acid: 18 mg or 35 mg 3 times daily as needed or scheduled; maximum dose: 105 mg/day.

Ankylosing spondylitis

Ankylosing spondylitis:

Dysmenorrhea

Dysmenorrhea:

Oral: Diclofenac potassium or sodium formulations: 150 mg/day in divided doses (may choose immediate release [given in 2 to 4 divided doses] or delayed release [given in 2 to 4 divided doses]); may administer 75 to 100 mg as an initial loading dose followed by a maintenance dose; maximum dose (after day 1): 150 mg/day. Begin at menses onset or 1 to 2 days prior to onset of menses for severe symptoms; usual duration: 1 to 5 days (Ref).

Gout, treatment, acute flares

Gout, treatment, acute flares (off-label use):

Oral: Diclofenac potassium or sodium formulations: 100 to 150 mg/day in divided doses (may choose immediate release [given in 2 to 4 divided doses], delayed release [given in 2 to 4 divided doses], or extended release [given once daily]). Initiate within 24 to 48 hours of flare onset; reduce dose as symptoms improve. Discontinue a few days after resolution of clinical signs (usual total duration: 5 to 7 days); longer duration may be required if therapy is delayed (Ref).

Migraine, acute treatment

Migraine, acute treatment:

Note: For use as monotherapy in mild to moderate attacks not associated with vomiting or severe nausea; may be used in combination with triptans for severe migraine (Ref).

Oral (powder for oral solution or IR tablet): 50 to 100 mg as a single dose (Ref).

Osteoarthritis

Osteoarthritis:

Oral: Diclofenac acid: 35 mg 3 times daily; maximum dose: 105 mg/day.

Rectal (Canadian product): Substitute for the final oral daily dose: Insert 50 mg or 100 mg suppository as a single dose.

Rheumatoid arthritis

Rheumatoid arthritis:

Oral: Diclofenac potassium or sodium formulations: 100 mg/day in divided doses (may choose immediate release [given in 2 to 4 divided doses], delayed release [given in 2 to 4 divided doses], or extended release [given once or twice daily]); if needed, may increase to a maximum dose of 200 mg/day in divided doses (Ref). Note: For the ER formulation, the maximum dose should be given in 2 divided doses according to the manufacturer.

Rectal (Canadian product): Substitute for the final oral daily dose: Insert 50 mg or 100 mg suppository as a single dose.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Oral, rectal:

Altered kidney function:

CrCl ≥60 mL/minute: No dosage adjustment necessary (Ref).

CrCl >30 to <60 mL/minute: No dosage adjustment necessary (Ref). However, use of analgesics other than nonsteroidal anti-inflammatory drugs may be preferred. If necessary, use the lowest effective dose for the shortest duration possible; avoid in patients at high risk for acute kidney injury (ie, volume depleted, hypotensive, older adults, or taking concurrent nephrotoxic medications) (Ref).

CrCl ≤30 mL/minute: Avoid use due to increased risk of acute kidney injury (Ref).

Hemodialysis, intermittent (thrice weekly): Not expected to be significantly dialyzable (highly protein bound) (Ref): No dosage adjustment necessary. Avoid use in patients with residual kidney function (Ref).

Peritoneal dialysis: No dosage adjustment necessary. Avoid use in patients with residual kidney function (Ref).

CRRT: Avoid use (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Avoid use (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution to avoid adverse effects and discontinue if hepatic function worsens.

Dosing: Older Adult

Unless alternative agents are ineffective and a gastroprotective agent can be administered, avoid short-term scheduled use in combination with corticosteroids, anticoagulants, or antiplatelet agents or chronic use with or without medications that increase risk for bleeding (Ref).

Refer to adult dosing; initiate using lowest recommended dose and frequency.

Dosing: Pediatric

(For additional information see "Diclofenac (systemic): Pediatric drug information")

Dosage guidance:

Dosing: Use the lowest effective dose for the shortest duration.

Dosage form information: Different oral formulations are not bioequivalent; do not interchange products.

Oral:

Acute pain

Acute pain (mild to moderate): Children ≥12 years and Adolescents: Immediate-release capsule (Zipsor): Oral: 25 mg 4 times daily (Ref).

Juvenile idiopathic arthritis

Juvenile idiopathic arthritis: Limited data available: Children and Adolescents: Immediate-release tablet: Oral: 2 to 3 mg/kg/day in divided doses 2 to 3 times daily; maximum daily dose: 150 mg/day (Ref).

Migraine

Migraine: Limited data available: Children ≥12 years and Adolescents: Powder for oral solution (eg, Cambia): Oral: 50 mg (1 packet) as a single dose at onset of migraine (Ref).

Rectal: Rectal formulation not available in the United States. Note: Approved indications, strengths, and ages vary by country; see product-specific labeling for details.

Juvenile idiopathic arthritis

Juvenile idiopathic arthritis: Limited data available: Children: Suppository (12.5 mg or 25 mg only): Rectal: 1 to 3 mg/kg/day in divided doses 2 to 3 times daily (Ref).

Osteoarthritis

Osteoarthritis: Limited data available: Adolescents ≥16 years: Suppository (50 mg or 100 mg): Rectal: Insert 50 or 100 mg suppository at bedtime as a substitute for the last daily oral dose; maximum daily dose: 100 mg/day (oral and rectal) (Ref).

Postoperative pain

Postoperative pain: Limited data available: Rectal suppository (12.5, 25, or 50 mg): Children and Adolescents: Suppository (12.5 mg, 25 mg, or 50 mg): Rectal: Initial dose: 1 to 2 mg/kg/dose once followed by 1 mg/kg/dose 3 times daily; round dose to nearest available suppository size; maximum single dose: 50 mg/dose; maximum daily dose: 3 mg/kg/day; treatment should not exceed 4 days duration (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Children and Adolescents: There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; some experts have suggested the following:

KDIGO 2012 guidelines provide the following recommendations for NSAIDs (Ref):

eGFR 30 to <60 mL/minute/1.73 m²: Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury

eGFR <30 mL/minute/1.73 m²: Avoid use.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, may require dosage adjustment due to extensive hepatic metabolism.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions may be reported for diclofenac specifically or as class effects for nonsteroidal anti-inflammatory drugs.

>10%:

Cardiovascular: Edema (33%)

Gastrointestinal: Nausea (3% to 14%)

1% to 10%:

Cardiovascular: Hypertension (2%)

Dermatologic: Diaphoresis (1%), pruritus (7%), skin rash

Gastrointestinal: Abdominal pain (4% to 7%), constipation (8%), diarrhea (6%), duodenal ulcer, dyspepsia (2%), flatulence (2% to 3%), gastric ulcer, gastrointestinal hemorrhage, gastrointestinal perforation, heartburn, upper abdominal pain (3%), vomiting (3% to 6%)

Hematologic & oncologic: Anemia, prolonged bleeding time

Hepatic: Increased liver enzymes, increased serum alanine aminotransferase (2%), increased serum aspartate aminotransferase

Nervous system: Dizziness (1% to 4%), drowsiness (3%), headache (4% to 10%)

Neuromuscular & skeletal: Back pain (4%), limb pain (3%), musculoskeletal pain (4%)

Otic: Tinnitus

Renal: Increased serum creatinine (2%), renal function abnormality

Respiratory: Sinusitis (3%)

<1%:

Cardiovascular: Acute myocardial infarction, cardiac arrhythmia, cardiac failure, flushing, hypotension, palpitations, syncope, tachycardia, vasculitis

Dermatologic: Alopecia, ecchymoses, erythema multiforme, exfoliative dermatitis, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria

Endocrine & metabolic: Hyperglycemia, weight changes

Gastrointestinal: Change in appetite, colitis, eructation, esophagitis, gastritis, glossitis, hematemesis, melena, pancreatitis, peptic ulcer, stomatitis, xerostomia

Genitourinary: Cystitis, dysuria, hematuria, oliguria, proteinuria

Hematological & oncologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, leukopenia, lymphadenopathy, pancytopenia, purpuric disease, rectal hemorrhage, thrombocytopenia

Hepatic: Fulminant hepatitis, hepatic failure, hepatic necrosis, hepatitis, jaundice

Hypersensitivity: Anaphylaxis, angioedema

Infection: Infection, sepsis

Nervous system: Abnormal dreams, anxiety, coma, confusion, depression, hallucination, insomnia, malaise, meningitis, nervousness, paresthesia, seizure, vertigo

Neuromuscular: Asthenia, tremor

Ophthalmic: Blurred vision, conjunctivitis

Otic: Auditory impairment

Renal: Interstitial nephritis, polyuria, renal failure syndrome

Respiratory: Asthma, dyspnea, pneumonia, respiratory depression

Miscellaneous: Fever

Frequency not defined:

Cardiovascular: Cerebrovascular accident, coronary thrombosis

Endocrine & metabolic: Fluid retention

Gastrointestinal: Gastrointestinal inflammation

Hepatic: Hepatotoxicity

Renal: Renal papillary necrosis

Postmarketing:

Genitourinary: Azotemia (Gurwitz 1990)

Immunologic: Drug reaction with eosinophilia and systemic symptoms

Contraindications

Hypersensitivity to diclofenac (eg, anaphylactoid reactions, serious skin reactions) or bovine protein (Zipsor only) or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs; use in the setting of coronary artery bypass graft surgery.

Canadian labeling: Additional contraindications (not in US labeling): Severe uncontrolled heart failure; active gastric/duodenal/peptic ulcer; active GI bleed or perforation, regional ulcer or enteritis, gastritis, ulcerative colitis, or recurrent ulceration; cerebrovascular bleeding or other bleeding disorders; inflammatory bowel disease; severe hepatic impairment; active hepatic disease; severe renal impairment (CrCl <30 mL/minute) or deteriorating renal disease; known hyperkalemia; patients <16 years of age (suppository, tablet) or <18 years of age (packet only); breastfeeding; pregnancy (third trimester); recent history of bleeding or inflammatory lesions of rectum/anus (suppository only).

Warnings/Precautions

Concerns related to adverse effects:

• Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with "aspirin triad" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Contraindicated in patients who experience bronchospasm, asthma, rhinitis, or urticaria with nonsteroidal anti-inflammatory drug (NSAID) or aspirin therapy.

• Cardiovascular events: [US Boxed Warning]: NSAIDs cause an increased risk of serious (and potentially fatal) adverse cardiovascular thrombotic events, including MI and stroke. Risk may occur early during treatment and may increase with duration of use. Relative risk appears to be similar in those with and without known cardiovascular disease or risk factors for cardiovascular disease; however, absolute incidence of serious cardiovascular thrombotic events (which may occur early during treatment) was higher in patients with known cardiovascular disease or risk factors and in those receiving higher doses. New-onset hypertension or exacerbation of hypertension may occur (NSAIDs may also impair response to ACE inhibitors, thiazide diuretics, or loop diuretics); may contribute to cardiovascular events; monitor blood pressure; use with caution in patients with hypertension. May cause sodium and fluid retention; use with caution in patients with edema. Avoid use in heart failure (FDA 2015). Avoid use in patients with recent MI unless benefits outweigh risk of cardiovascular thrombotic events. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.

• CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.

• Drug reaction with eosinophilia and systemic symptoms: Potentially serious, sometimes fatal, drug reaction with eosinophilia and systemic symptoms (DRESS), also known as multiorgan hypersensitivity reactions, has been reported with NSAIDs. Monitor for signs and symptoms (eg, fever, rash, lymphadenopathy, eosinophilia) in association with other organ system involvement (eg, hepatitis, nephritis, hematological abnormalities, myocarditis, myositis). Early symptoms of hypersensitivity reaction (eg, lymphadenopathy, fever) may occur without rash; discontinue therapy and further evaluate if DRESS is suspected.

• GI events: [US Boxed Warning]: NSAIDs cause an increased risk of serious GI inflammation, ulceration, bleeding, and perforation (may be fata); elderly patients and patients with history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. These events may occur at any time during therapy and without warning. Avoid use in patients with active GI bleeding. In patients with a history of acute lower GI bleeding, avoid use of non-aspirin NSAIDs, especially if due to angioectasia or diverticulosis (Strate 2016). Use caution with a history of GI ulcers, concurrent therapy known to increase the risk of GI bleeding (eg, aspirin, anticoagulants and/or corticosteroids, selective serotonin reuptake inhibitors), advanced hepatic disease, coagulopathy, smoking, use of alcohol, or in elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt 2008).

• Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).

• Hepatic effects: Transaminase elevations have been reported with use; closely monitor patients with any abnormal LFT. Rare, sometimes fatal severe hepatic reactions (eg, fulminant hepatitis, hepatic necrosis, hepatic failure) have occurred with NSAID use; discontinue immediately if clinical signs or symptoms of liver disease develop or if systemic manifestations occur.

• Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE inhibitors). Monitor potassium closely.

• Renal effects: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation (usually reversible). Patients with impaired renal function, dehydration, hypovolemia, heart failure, hepatic impairment, those taking diuretics and ACE inhibitors, and elderly patients are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Long-term NSAID use may result in renal papillary necrosis and other renal injury.

• Skin reactions/hypersensitivity: NSAIDs may cause potentially fatal serious skin adverse events, including drug reaction with eosinophilia and systemic symptoms, exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); may occur without warning; discontinue use at first sign of skin rash (or any other hypersensitivity).

Disease-related concerns:

• Aseptic meningitis: May increase the risk of aseptic meningitis (rarely), especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.

• Asthma: Contraindicated in patients with aspirin-sensitive asthma; severe, potentially fatal bronchospasm may occur. Use caution in patients with other forms of asthma.

• Bariatric surgery: Gastric ulceration: Avoid chronic use of oral nonselective NSAIDs after bariatric surgery; development of anastomotic ulcerations/perforations may occur (Bhangu 2014; Mechanick 2020). Short-term use of celecoxib or IV ketorolac are recommended as part of a multimodal pain management strategy for postoperative pain (Chou 2016; Horsley 2019; Thorell 2016).

• Coronary artery bypass graft surgery: [US Boxed Warning]: Use is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. Risk of MI and stroke may be increased with use following CABG surgery.

• Hepatic impairment: Use with caution in patients with hepatic impairment; reduced doses may be required due to extensive hepatic metabolism. Patients with advanced hepatic disease are at an increased risk of GI bleeding and kidney failure with NSAIDs (AASLD [Biggins 2021]; AASLD [Runyon 2013]).

• Renal impairment: Avoid use in patients with advanced renal disease; discontinue use with persistent or worsening abnormal renal function tests.

Special populations:

Older adult: Older adult patients are at greater risk for serious GI, cardiovascular, and/or renal adverse events.

Dosage form specific issues:

• Oral solution: May contain phenylalanine.

• Zipsor: Contains gelatin; use is contraindicated in patients with history of hypersensitivity to bovine protein.

Other warnings/precautions:

• Appropriate use: Oral solution: Indicated only for the acute treatment of migraine (not indicated for migraine prophylaxis or cluster headache). Acute migraine agents (eg, NSAIDs, triptans, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse.

• Bioequivalence: Different formulations of oral diclofenac are not bioequivalent, even if the milligram strength is the same; do not interchange products.

• Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral, as acid:

Zorvolex: 18 mg [DSC], 35 mg [DSC] [contains fd&c blue #1 (brilliant blue), fd&c blue #2 (indigotine,indigo carmine)]

Generic: 35 mg [DSC]

Capsule, Oral, as potassium:

Zipsor: 25 mg [contains gelatin (bovine)]

Generic: 25 mg

Packet, Oral, as potassium:

Cambia: 50 mg (1 ea, 9 ea) [anise-mint flavor]

Generic: 50 mg (1 ea, 9 ea)

Tablet, Oral, as potassium:

Cataflam: 50 mg [DSC]

Lofena: 25 mg

Generic: 25 mg, 50 mg

Tablet Delayed Release, Oral, as sodium:

Generic: 25 mg, 50 mg, 75 mg

Tablet Extended Release 24 Hour, Oral, as sodium:

Generic: 100 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (Diclofenac Potassium Oral)

25 mg (per each): $16.09 - $17.69

Capsules (Zipsor Oral)

25 mg (per each): $18.62

Pack (Cambia Oral)

50 mg (per each): $118.26

Pack (Diclofenac Potassium(Migraine) Oral)

50 mg (per each): $99.87 - $106.43

Tablet, 24-hour (Diclofenac Sodium ER Oral)

100 mg (per each): $2.70 - $2.81

Tablet, EC (Diclofenac Sodium Oral)

25 mg (per each): $1.42

50 mg (per each): $0.80 - $1.47

75 mg (per each): $0.56 - $1.77

Tablets (Diclofenac Potassium Oral)

25 mg (per each): $34.45 - $38.00

50 mg (per each): $2.75 - $2.76

Tablets (Lofena Oral)

25 mg (per each): $38.71

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Packet, Oral, as potassium:

Cambia: 50 mg (1 ea, 3 ea, 9 ea) [contains aspartame, saccharin sodium]

Suppository, Rectal:

Voltaren: 50 mg (30 ea); 100 mg ([DSC])

Generic: 50 mg (30 ea); 100 mg ([DSC])

Tablet, Oral, as potassium:

Voltaren Rapide: 50 mg [contains corn starch]

Generic: 50 mg

Tablet Delayed Release, Oral, as sodium:

Voltaren: 50 mg [DSC] [contains corn starch]

Generic: 25 mg, 50 mg

Tablet Extended Release 24 Hour, Oral, as sodium:

Voltaren SR: 75 mg [DSC] [contains polysorbate 80]

Voltaren SR: 100 mg

Generic: 75 mg, 100 mg

Administration: Adult

Oral: Do not crush delayed-release or ER tablets. May administer IR formulations with food or milk to avoid gastric distress.

Cambia, Zorvolex: Administering with food may cause a reduction in effectiveness.

Bariatric surgery: Tablet, delayed and extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Do not cut, crush, or chew. Nonsteroidal anti-inflammatory drugs are generally not recommended for regular use postbariatric surgery.

Administration: Pediatric

Oral:

Immediate release: Administer with milk or food to decrease GI upset; take with full glass of water to enhance absorption.

Oral solution: Empty contents of packet into 1 to 2 ounces (30 to 60 mL) of water (do not use other liquids); mix well and administer right away. Administering with food may reduce effectiveness.

Rectal: Suppository (products not available in US): Remove plastic film prior to insertion; insert well into the rectum; for best results, bowels should be empty prior to insertion (Ref).

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Cambia: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022165s013s014lbl.pdf#page=23

Cataflam: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM135935.pdf

NSAID: https://www.fda.gov/media/79842/download

Voltaren-XR: https://www.fda.gov/media/98046/download

Zorvolex: https://www.fda.gov/media/87010/download

Use: Labeled Indications

Ankylosing spondylitis: Acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis.

Dysmenorrhea: Treatment of primary dysmenorrhea.

Migraine, acute treatment: Acute treatment of migraine attacks with or without aura in adults.

Osteoarthritis: Relief of signs and symptoms of osteoarthritis.

Pain, acute: Relief of mild to moderate acute pain in pediatric patients ≥12 years of age (Zipsor) and adults.

Rheumatoid arthritis: Relief of signs and symptoms of rheumatoid arthritis.

Use: Off-Label: Adult

Gout, treatment, acute flares

Medication Safety Issues

Sound-alike/look-alike issues:

Diclofenac may be confused with Diflucan

Cataflam may be confused with Catapres

Voltaren may be confused with traMADol, Ultram, Verelan

Older Adult: High-Risk Medication:

Beers Criteria: Diclofenac is identified in the Beers Criteria as a potentially inappropriate medication to be avoided for chronic use in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high-risk category (eg, older than 75 years of age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). In addition, avoid for short-term scheduled use in combination with oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents unless alternatives are ineffective and patient can receive concomitant gastroprotective agent (Beers Criteria [AGS 2023]).

International issues:

Diclofenac may be confused with Duphalac brand name for lactulose [multiple international markets]

Flexin: Brand name for diclofenac [Argentina], but also the brand name for cyclobenzaprine [Chile] and orphenadrine [Israel]

Flexin [Argentina] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], and ofloxacin [US]

Metabolism/Transport Effects

Substrate of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (major), CYP2D6 (minor), CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits UGT1A6

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. Risk C: Monitor therapy

Abrocitinib: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the antiplatelet effect of Abrocitinib. Risk X: Avoid combination

Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination

Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties. Risk C: Monitor therapy

Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination. Risk C: Monitor therapy

Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. Risk C: Monitor therapy

Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. Risk C: Monitor therapy

Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). Risk X: Avoid combination

Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Risk C: Monitor therapy

Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function. Risk C: Monitor therapy

Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy

Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Apixaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Artesunate: Diclofenac (Systemic) may increase serum concentrations of the active metabolite(s) of Artesunate. Risk C: Monitor therapy

Bemiparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. Risk C: Monitor therapy

Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. Risk C: Monitor therapy

Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs. Risk D: Consider therapy modification

Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. Risk C: Monitor therapy

Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. Risk C: Monitor therapy

Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Risk C: Monitor therapy

CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs). Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs. Risk D: Consider therapy modification

CYP2C9 Inducers (Moderate): May decrease the serum concentration of Diclofenac (Systemic). Risk C: Monitor therapy

CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Diclofenac (Systemic). Risk C: Monitor therapy

Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy

Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone. Risk X: Avoid combination

Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. Risk C: Monitor therapy

Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the hyponatremic effect of Desmopressin. Risk C: Monitor therapy

Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. Risk C: Monitor therapy

Diosmin: May increase the serum concentration of Diclofenac (Systemic). Risk C: Monitor therapy

Drospirenone-Containing Products: May enhance the hyperkalemic effect of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Enoxaparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue nonsteroidal anti-inflammatory agents (NSAIDs) prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. Risk C: Monitor therapy

Heparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required. Risk D: Consider therapy modification

Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required. Risk D: Consider therapy modification

Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur. Risk C: Monitor therapy

Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Risk C: Monitor therapy

HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. Risk C: Monitor therapy

Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. Risk C: Monitor therapy

Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination

Ketorolac (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Ketorolac (Systemic). Risk X: Avoid combination

Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased. Risk C: Monitor therapy

Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. Management: Consider reducing the lithium dose when initiating a NSAID. Monitor for increased lithium therapeutic/toxic effects if a NSAID is initiated/dose increased, or decreased effects if a NSAID is discontinued/dose decreased. Risk D: Consider therapy modification

Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended. Risk D: Consider therapy modification

Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Risk C: Monitor therapy

Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. Risk X: Avoid combination

MetFORMIN: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of MetFORMIN. Risk C: Monitor therapy

Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate. Management: Avoid coadministration of higher dose methotrexate (such as that used for the treatment of oncologic conditions) and NSAIDs. Use caution if coadministering lower dose methotrexate and NSAIDs. Risk D: Consider therapy modification

Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). Risk C: Monitor therapy

Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. Risk X: Avoid combination

Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk for gastrointestinal toxicity is increased. Risk X: Avoid combination

Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti-inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities. Risk D: Consider therapy modification

Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. Risk C: Monitor therapy

Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Risk C: Monitor therapy

Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents. Risk C: Monitor therapy

Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination

Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Polyethylene Glycol-Electrolyte Solution: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. Risk C: Monitor therapy

Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. Risk C: Monitor therapy

Potassium Salts: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium Salts. Risk C: Monitor therapy

Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk C: Monitor therapy

PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate. Management: Avoid coadministration of pralatrexate with nonsteroidal anti-inflammatory drugs (NSAIDs). If coadministration cannot be avoided, closely monitor for increased pralatrexate serum levels or toxicity. Risk D: Consider therapy modification

Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). Risk C: Monitor therapy

Quercetin: May increase the serum concentration of Diclofenac (Systemic). Risk C: Monitor therapy

Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. Risk C: Monitor therapy

Resveratrol: May increase the serum concentration of Diclofenac (Systemic). Risk C: Monitor therapy

Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin. Risk D: Consider therapy modification

Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk. Risk D: Consider therapy modification

Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Risk C: Monitor therapy

Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification

Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Risk C: Monitor therapy

Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). Risk C: Monitor therapy

Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk. Risk D: Consider therapy modification

Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination

Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. Risk C: Monitor therapy

Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Tricyclic Antidepressants: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. Risk X: Avoid combination

Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. Risk C: Monitor therapy

Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. Risk C: Monitor therapy

Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists. Management: Consider alternatives to this combination when possible. If the combination must be used, monitor coagulation status closely and advise patients to promptly report any evidence of bleeding or bruising. Risk D: Consider therapy modification

Voriconazole: May increase the serum concentration of Diclofenac (Systemic). Risk C: Monitor therapy

Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Reproductive Considerations

Nonsteroidal anti-inflammatory drugs (NSAIDs) may delay or prevent rupture of ovarian follicles. This may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in patients having difficulty conceiving or those undergoing investigation of fertility.

Based on available information, NSAIDs can be continued in patients with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).

Pregnancy Considerations

Diclofenac crosses the placenta.

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) close to conception may be associated with an increased risk of miscarriage due to cyclooxygenase-2 inhibition interfering with implantation (Bermas 2014; Bloor 2013).

Birth defects have been observed following in utero NSAID exposure in some studies; however, data are conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage, have been observed in the fetus/neonate following in utero NSAID exposure (Bermas 2014; Bloor 2013). Maternal NSAID use may cause fetal renal dysfunction leading to oligohydramnios. Although rare, this may occur as early as 20 weeks' gestation and is more likely to occur with prolonged maternal use. Oligohydramnios may be reversible following discontinuation of the NSAID (Dathe 2019; FDA 2020). In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).

Maternal use of NSAIDs should be avoided beginning at 20 weeks' gestation. If NSAID use is necessary between 20 and 30 weeks' gestation, limit use to the lowest effective dose and shortest duration possible; consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours and discontinue the NSAID if oligohydramnios is found (FDA 2020). Because NSAIDs may cause premature closure of the ductus arteriosus, prescribing information for diclofenac specifically states use should be avoided starting at 30 weeks' gestation.

Based on available information, NSAIDs can be continued during the first 2 trimesters of pregnancy in patients with rheumatic and musculoskeletal diseases; use in the third trimester is not recommended (ACR [Sammaritano 2020]).

NSAIDs may be used as part of a multimodal approach to pain relief following cesarean delivery (ACOG 2019).

Treatment for migraine headaches in pregnant patients should be individualized (AHS [Ailani 2021]). The acute treatment of migraine headaches during pregnancy should be initiated with an agent other than an NSAID. If an NSAID is needed as second-line therapy, treatment should be limited to the second trimester and total duration of therapy should be no longer than 48 hours. An NSAID other than diclofenac may be preferred (ACOG 2022).

Breastfeeding Considerations

Diclofenac may be present in breast milk.

The milk concentration of a woman treated with oral diclofenac 150 mg/day was reported to be 100 mcg/L (equivalent to an infant dose of ~0.03 mg/kg/day). Diclofenac was not detected in breast milk when 100 mg/day orally was administered to 12 women for 7 days or as a single dose of 50 mg IM immediately postpartum.

Nonopioid analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), are preferred for breastfeeding patients who require pain control peripartum or for surgery outside of the postpartum period (ABM [Martin 2018]; ABM [Reece-Stremtan 2017]). NSAIDs are considered compatible for use in patients with rheumatic and musculoskeletal diseases who are breastfeeding; agents with a short half-life and established safety data in infants may be preferred (ACR [Sammaritano 2020]). NSAIDs may be used to treat acute migraine in lactating patients (ACOG 2022).

The manufacturer recommends that the decision to breastfeed during therapy consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Maternal use of NSAIDs should be avoided if the breastfeeding infant has platelet dysfunction, thrombocytopenia, or a ductal-dependent cardiac lesion (ABM [Martin 2018]; ABM [Reece-Stremtan 2017]; Bloor 2013).

Dietary Considerations

Oral immediate-release formulations may be taken with food to decrease GI distress. However, food may reduce effectiveness of oral solution and diclofenac acid (capsule). Some products may contain phenylalanine.

Monitoring Parameters

CBC, chemistry profile, weight, edema, LFTs (baseline and periodically during chronic therapy), renal function (serum BUN, serum creatinine, urine output); occult blood loss; BP; observe for bleeding, bruising; GI effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation.

Mechanism of Action

Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties

Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity, inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.

Pharmacokinetics (Adult Data Unless Noted)

Note: Characteristics of various oral dosage forms are similar unless specifically noted below.

Absorption: ~50% (systemically available).

Distribution: ~1.3 to 1.4 L/kg.

Protein binding: >99%, primarily to albumin.

Metabolism: Hepatic; undergoes first-pass metabolism; forms several metabolites (1 with weak activity).

Bioavailability: 55%.

Half-life elimination: ~2 hours; ~1 hour (liquid filled capsule [Zipsor]).

Time to peak, serum: Note: Fasted values reported; may be delayed with food.

Cambia: ~0.25 hours.

Cataflam, Zorvolex: ~1 hour.

Zipsor: ~0.47 ± 0.17 hour.

Tablet, delayed release (diclofenac sodium): 2.3 hours.

Tablet, extended release (diclofenac sodium): 5.3 hours.

Excretion: Urine (~65%); bile (~35%).

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Almiral | Cataflam | Clofast p | Clofen | Diclo | Diclo k | Dicloflam k | Diclogesic | Diclomax | Diclopid | Fast flam | Infla ban | Joflam | K flam | Neoflam | Olfen | Rhumalgan | Rofenac | Tabiflex | Voldic K | Voltagesic | Voltaren | Voltfenac | Voltic | Votrex | Zorvolex;
(AR) Argentina: Acloxigenac | Ainedif | Aktiosan | Aldoron nf | Algioxib | Anaflex | Anaflex mujer perlas | Banoclus | Befol | Befol ap retard | Blokium | Blokium p | Calmoflex | Cataflam | Curinflam | Curinflam a.p. | Curinflam gesic | D.f.n | Damixa | Diastone | Diclac | Diclocalm | Diclofenac cevallos | Diclofenac df | Diclofenac gen med | Diclofenac hex 50 d | Diclofenac hexa | Diclofenac hexa retard | Diclofenac Hlb | Diclofenac kilab | Diclofenac larjan | Diclofenac northia | Diclofenac potasio | Diclofenac puntanos | Diclofenac richet | Diclofenac surar pharma | Diclofenac techsphere | Diclofenac teva | Diclogesic | Diclogrand | Diclolabsa | Diclolabsa potasico | Diclolam | Diclomar | Diclonex | Diclonovag | Diclopoen | Diclovann k | Difenac | Dioxaflex | Dioxaflex cb | Dioxaflex Migra | Disipan | Disipan nf | Dolo tomanil | Dolofenac | Dolvan | Doxtran | Faboflem | Fada diclofenac | Flexana | Flexipen | Flexiplen | Flexiplen retard | Flogenac | Flotac | Fluxpiren | Ibuxim diclo | Imanol | Klonafenac | Lafenac | Lorbifenac | Metaflex | Metaflex n.f. | Nalgiflex | Norviken vent3 | Oxa | Oxa 75 | Reumosan | Rodinac | Silfox | Tomanil | Venzidiak | Vesalion | Viartril nf | Vimultisa | Virobron nf | Volforte | Volmas | Voltaren | Voltaren dolo | Voltaren migra | Xedenol;
(AT) Austria: Dedolor | Deflamat | Diclac | Diclachexal | Diclobene | Diclobene uno | Diclofenac | Diclofenac 1A Pharma | Diclofenac G.L. | Diclofenac genericon pharma | Diclofenac kabi | Diclofenac sandoz | Diclomelan | Diclostad | Dolpasse | Fenaren | Tratul | Voltaren | Voltaren dolo | Voltaren retard;
(AU) Australia: Apo diclofenac | Apohealth anti-Inflammatory pain relief | Blooms the chemist anti inflammatory pain relief | Chemists own diclofenac 25 | Clonac | Diclac | Diclofenac | Diclofenac an | Diclofenac sandoz | Diclohexal | Dinac | Fenac | Imflac | Inflamax | Pharmacor diclofenac | Pharmacy action diclofenac 25 | Pharmacy choice diclofenac | Priceline pharmacy diclofenac | Trust difenac | Viclofen | Voltaren | Voltaren rapid;
(BD) Bangladesh: A fenac | A-fenac k | Alcofen | Almiral | Alterin | Alterin tr | Anfenac | Anodyne | Anuva | Apain | C-fenac | Cataflam | Clofen | Clofenac | Clonac | Cofac | Decafen | Denac | Diclo | Dicloberl | Diclofen | Diclofenac | Diclomol | Diclonac | Diclora | Diclorex | Diclotab | Diclowal | Difen | Difenac | Dilock | Dinac | Dix | Edifenac | Erdon | Fenac | Fentab | Ficlon | G-diclofenac | Gefenac | Genac | Hi fenac | Hitflam | Inflacin | Intafenac | Kalinac | Lardon | Locopain | Lonac | Medifen | Megafen | Mobifen | Moov | Movonac | Nasida | Neofen | Neofenac | Nopain | Norfen | Nortid | O clofen | Orafen | Orfenac | Orgafen tr | Penac | Proladin | Pronac | Refain | Reutren | Ronac | Rotafen | S-fenac | Sifen | Tenac tr | Tolfenac | Ultaran | Ultrafen | Verdan | Volcan | Volfen | Voltalin | Voltanac | Voltaren | Voltarol | Voltid | Vurdon | Vurdon sr;
(BE) Belgium: Cataflam | Diclofemed | Diclofenac bexal | Diclofenac eg | Diclofenac eurogenerics | Diclofenac lagepha | Diclofenac ratiopharm | Diclofenac sandoz | Diclofenac teva | Diclofenac teva generics belgium | Diclotop | Docdiclofe | Motifene | Polyflam | Voltaren;
(BF) Burkina Faso: Diclac | Diclo | Diclo denk | Dicloberl | Diclofenac ubigen | Diclopal | Dicofen | Dolex sr | Dolotren | Dynapar ec | Dynapar sr | Flotac | Olfen | Philco diclo | Voltarene | Voltarene dolo;
(BG) Bulgaria: Almiral | Areston instant | Cataflam | Diclac | Diclofenac | Diclofenac duo | Feloran | Naklofen | Naklofen duo | Veral | Voltaren | Voltaren dolo | Vurdon;
(BR) Brazil: Abiflan | Artren | Augelit | Baldaflam | Baldaren | Belfaren | Benevran | Bexai | Biofenac | Cataflam | Cataflex | Catalgem | Cataren | Cinaflan | Clofen k | Clofen s | Clofenak | Clofenid | Decorfen | Deltaren | Desinflex | Desinflex retard | Dflam | Diclac | Diclo p | Diclof | Diclofan | Diclofarma | Diclofen | Diclofenaco colestiramina | Diclofenaco de colestiramina | Diclofenaco potasico | Diclofenaco potassico | Diclofenaco sodica | Diclofenaco sodico | Diclofenax | Diclokalium | Diclonaco | Diclonatrium | Diclonax | Diclonil | Diclosod | Diclosodico | Dicloton | Dicoplex | Difenan | Dioxaflex | Dkaflan | Dnaren | Dorflan | Dorgen | Dryltac | Fenaflan | Fenaflan d | Fenaren | Fenburil | Fisioren | Fladon | Flamalgen | Flamatrat | Flanakin | Flanaren | Flexamina | Flodin duo | Flogan | Flogiren | Flogonac | Flotac | Furp diclofenaco | Genoren | Globaren | Hiclofen | Hynaren | Infladex | Inflamax | Inflamex | Inflaren | Inflaren-k | Kindaren | Lfm diclofenaco de potassio | Lfm diclofenaco potassico | Luparen | Naclofan | Naclofen | Neotaflan | Neotaren | Nevralren | Olfen | Optamax | Poltax | Probenxil | Prodofenaco p | Resodic | Reuflen | Reumaren | Sifdiclop | Sifnaco | Sintofenac | Sodix | Somaflex ap | Tonaflan | Vendrex | Volflanil | Voltaflan | Voltaflex | Voltaren | Voltrix | Zotac;
(CH) Switzerland: Amavita dicloren | Coop vitality diclofenac | Deflamat | Diclac | Diclo-basan | Diclofenac actavis | Diclofenac adico | Diclofenac genericon | Diclofenac helvepharm | Diclofenac rivopharm | Ecofenac | Flector | Flector dolo forte | Inflamac | Inflamac 75 retard | Olfen | Olfen duo release | Tonopan | Tonopan forte | Tonopan neue formel | Voltaren | Voltaren dolo | Voltaren dolo forte | Voltaren Migraene;
(CI) Côte d'Ivoire: Adco diclofenac | Diclo pharma 5 | Diclocare | Diclofen | Diclofenac generis | Diclosha sr | Diclowal | Dicofen sr | Dolex | Dolex sr | Doloren | Dynapar aq | Dynapar sr | Flotac | Lofnac | Ronfenac | Rufenac | Xenid;
(CL) Chile: Artren | Autdol | Brevedol | Cataflam | Deflamat | Diclac | Diclofenaco | Diclotaren | Dignofenac | Elitiran | Flamesan | Flotac | Lertus | Merpal | Pevoran | Pirexyl | Piroflam | Pro lertus | Prolertus | Promerpal | Sipirac | Traumus | Turbogesic | Voltaren | Zorvolex;
(CN) China: Antine | Apo diclo | Bi ke | De fu ka | Di fu na | Diclac | Diclofenac sodium suppositories (ii) | Didofence sodium | Difene | Difnal | Fei ya ning | Fen jia tai | Fu ta jie | Fu ta lin | Ge de | Jing qing | Kaflan | Novolten | Olfen | Pu ta ning | Tian xin li de | Tong du ding | Voren | Votalin | Wan li shu | Xi shu | Xin pu fen | Yi er song | Yi ke | Yi ke lin | Yi lin | Zhi qing;
(CO) Colombia: Algifen | Artren | Artrites | Atiflan | Berifen | Cataflam | Clofenil | Cytectol | Dflam | Diclodol | Diclofenac | Diclofenaco | Diclofenaco retard | Diclofenaco sodico | Diclomelan | Diflenac | Diflotec | Dilofar | Dioxaflex | Dormex | Fastpain max | Fenaclide | Fenamed | Flamydol | Flotac | Klafenac-r | Lumbal | Palldoll qrp | Profenac | Quimar | Suifenac | Volfen | Voltaflex | Voltaren;
(CY) Cyprus: Areston;
(CZ) Czech Republic: Almiral | Apo diclo | Dicloalgan | Diclofen | Diclofenac | Diclofenac al | Diclofenac aurobindo | Diclofenac dr. muller pharma | Diclofenac duo chemark | Diclofenac duo pharmaswiss | Dicloreum | Dicuno | Dolmina | Ecofenac | Flamrase | Monoflam | Myogit | Olfen | Rewodina | Veral | Voltaren | Voltaren actigo extra;
(DE) Germany: Allvoran | Arthrex | Benfofen | Diclac | Diclac dispers | Diclac dispers akut | Diclac Dolo | Diclo | Diclo 1A pharma | Diclo AL akut | Diclo denk | Diclo Divido | Diclo kd | Diclo saar | Diclo sandoz | Diclo-attritin | Diclo-puren | Diclodoc | Diclofen | Diclofenac | Diclofenac actavis | Diclofenac al | Diclofenac atid | Diclofenac Dura | Diclofenac heunet | Diclofenac kalium AL | Diclofenac Kalium STADA | Diclofenac natrium micro labs | Diclofenac Nch | Diclofenac ratiopharm | Diclofenac sandoz | Diclofenac stada | Diclofenac Truw | Diclofenac zentiva | Diclofenbeta | Diclophlogont | Diclotin | Diclowal | Difene | Doragon | Duravolten | Effekton | Jenafenac | Jutafenac | Monoflam | Myogit | Optalidon Zahnschmerz | Prekursan | Rewodina | Rheumasan d | Sigafenac | Voltaren | Voltaren dolo | Voltaren resinat | Xelaran;
(DK) Denmark: Diclofenac pliva | Diclofenac ratiopharm | Diclosup | Fenacop | Vostar;
(DO) Dominican Republic: Acrofenan | Acteric | Agilac | Anflamat | Artricom | Artridene | Artrikpiran | Bergeron | Calozan | Campal | Cataclofen | Cataflam | Cedob | Cladonac | Curinflam | Diclo K | Diclo k | Diclo lp | Diclofar | Diclofel | Diclofenac | Diclofenac alfa | Diclofenac df | Diclofenac k | Diclofenac Lam | Diclofenac sodico | Diclofenac sodico calox | Diclofenaco | Diclofenaco cinfa | Diclofenaco mk | Diclofenaco potasico | Diclofenaco sodico | Diclohem P | Diclonova pot | Diclopharm | Dicloplex | Dicloplex Retard | Dicloquin | Diclowal | Diclowal s | Dicloxal P | Dignofenac | Diklason | Dioxaflex | Diril | Dolflam | Dolo Nav | Dolocure | Dolotren | Domiopass | Elifenac | Eslofenac | Fernasin | Flamydol | Flogozan | Flotac | Fustaren | Inadic | Katafenac | Lertus | Lufenac | Lunizol | Menafenac | Neurogesic | Ortoflex | Oxa | Oxa Uno | Oxaflex | Pentacxin | Ragofenac | Sadol | Suifenac | Viavox | Volfenac | Voltaren | Zorvolex;
(EC) Ecuador: Acteric | Artren | Berifen | Cataflam | Clofen | Deflamat | Desinflam | Diclo azul | Diclo cien | Diclo k | Diclo K | Diclocien | Diclofenac | Diclofenac apotex | Diclofenac mk | Diclofenaco | Diclofenaco genfar | Diclofenaco potasico | Diclofenaco rocnarf | Diclofenaco sodico | Diclowal | Dignofenac | Dioxaflex | Disflam K | Dolostop | Dynapar | Fenagen | Flamydol | Flenac | Flexen | Flexiplen | Flogam | Flotac | Gladox | Grofenac | Hit | Kroflenaco | Lertus | Librafenac | Libraflam | Merpal | Prolertus | Turbogesic | Volfenac | Voltaren | Voltaren dolo;
(EE) Estonia: Almiral | Cataflam | Diclac | Diclobene | Dicloberl | Diclofen | Diclofenac | Diclofenac stada | Diclomax | Diclomelan | Diclonac | Diclonat p | Diclophenac | Dicuno | Effekton | Feloran | Flogofenac | Inflamac | Naklofen | Naklofen duo | Olfen | Ortophen | Rewodina | Sanfinac | Veral | Voltaren | Voltarol | Volxol;
(EG) Egypt: Actifast | Adwiflam | Antiflam | Arthrofast | Cataflam | Declofenac | Declophen | Diclac | Diclasium | Diclofenac | Dicloferaz | Dicloflam | Diclonatrium | Diclorapid | Diclosp | Dolphin | Dolphin-k | Epifenac | Fenaclomex | Flotac | Meroflam | Mipaflam | Oflam | Olfen | Pharofen | Potafen | Protofenac | Rapidus | Rapiflam | Rheumarene | Romalex | Sigmafenac | Suppofen | Unirapecure | Voltaren | Voltinac k | Zacaglone | Zitoxanal;
(ES) Spain: Di | Diclofenaco aldo union | Diclofenaco alter | Diclofenaco aristo | Diclofenaco bayvit | Diclofenaco bexal | Diclofenaco cinfa | Diclofenaco clariana | Diclofenaco edigen | Diclofenaco lepori | Diclofenaco llorens | Diclofenaco mundogen | Diclofenaco normon | Diclofenaco ratiopharm | Diclofenaco rubio | Dolotren | Luase | Voltaren;
(ET) Ethiopia: Adiflam | Almiral | Cataflam | Clofenac sr | Declophen | Diclo denk | Diclo denk 100 retard | Dicloas | Diclofenac | Didlyn | Divido | Dofec | Dynapar ec | Epifenac | Fensupp | Regunac | Remethan | Voldic K | Voltaren | Voren;
(FI) Finland: Clofemex | Diclofenac | Diclofenac bmm pharma | Diclometin | Diclomex | Dicuno | Motifene | Trabona | Voltaren;
(FR) France: Diclofenac | Diclofenac arrow | Diclofenac biogaran LP | Diclofenac delbert | Diclofenac g gam | Diclofenac gnr | Diclofenac ivax | Diclofenac merck | Diclofenac mylan LP | Diclofenac rpg | Diclofenac sandoz | Diclofenac teva | Flector | Voldal | Voltarendolo | Voltarene | Voltarene LP | Xenid;
(GB) United Kingdom: Acoflam | Closteril | Defanac | Dexomon | Diclo sr | Diclofenac | Diclofenac arrow | Diclofenac arun | Diclofenac berk | Diclofenac cox | Diclofenac kent | Diclofenac sandoz | Dicloflex | Diclomax | Diclotard | Diclovol | Diclozip | Difenor | Digenac xl | Dyloject | Econac | Fenactol | Flamatak | Flamrase | Flexotard | Isclofen | Lofensaid | Rheumatac | Rhumalgan | Slofenac | Valdic | Valenac | Volraman | Volsaid | Voltaren | Voltarol | Voltarol Joint Pain | Voltarol p | Voltarol Pain-eze;
(GH) Ghana: Diclo dor | Diclofen | Diclonova | Ronfenac;
(GR) Greece: Anthraxiton | Contralg | Delimon | Evinopon | Fenoclof | Flefarmin | Javipren | Rheumavek | Ruvominox | Urigon | Vilonit | Voltaren | Voltarol acti go | Vurdon;
(HK) Hong Kong: A-fenac k | Almiral | Apo diclo | Artharen | Cataflam | Clofec | Clofenac | Diclofen | Diclofenac | Diclogesic | Dicofen | Difena | Difenac | Difenol | Difisal | Dinac | Dynapar sr | Erdon | Eunac | Eurofenac | Euroflam | Fenac | Fenadium | Inflanac | Lesflam | Olfen | Painoff | Prophenatin | Qualifenac | Remafen | Ren | Rhemofenax | Sawto | Synfenac | Taks | Turbogesic | Umeran sr 100 | Uniren | Vartelon | Vidaclofen | Volna-k | Volta | Volta t.m. | Voltaren | Volton | Voren | Votan;
(HR) Croatia: Diclac duo | Diclo duo | Naklofen | Naklofen duo | Voltaren | Voltaren forte | Voltaren rapid;
(HU) Hungary: Cataflam | Cataflam dolo | Cataflam dolo rapid | Cataflam v | Diclac | Diclofenac al | Diclofenac stada | Diclomel | Diflam | Flector dolo rapid | Fortedol | Huma-difenac | Olfen | Voltaren dolo;
(ID) Indonesia: Araclof | Berifen | Cataflam | Catanac | Clofecon | Deflamat | Diaflam | Dicloflam | Diclophlogont | Diflam | Eflagen | Erphaflam | Exaflam | Fenaren | Flamic | Flamigra | Flazen | Galtaren | Gratheos | Inflam | Kadiflam | Kaditic | Kaflam | Kamaflam | Linac | Matsunaflam | Megatic | Merflam | Mirax | Nacoflar | Nadifen | Nadiflam | Neurofenac | Nichoflam | Nilaren | Potazen | Proklaf | Reflamid | Renadinac | Renvol | Scanaflam | Scantaren | Tirmaclo | Voltaren | Volten | Voren | Yariflam | Zelona | Zorvolex;
(IE) Ireland: Cataflam | Diclac | Diclo | Diclomax | Diclomel | Difene | Kyflam | Vologen | Voltaren | Voltarol;
(IL) Israel: Betaren | Cataflam | Voltaren;
(IN) India: Aclomax | Activa | Adiflam | Agile | Agile-d | Agile-k | Aglofen | Alapen | Aldinac | Alkoran | Anaida | Antiflame | Aquagesic | Ardis | Argesic | Ark | Artifen | Artilov | Clofac | Clofenac | Daclotenac | Dan | Deccaran | Decifen | Defenac | Delta-k | Demo | Denac | Dici-k | Diclo | Diclo k | Dicloact | Diclodol | Diclodyne | Diclofam | Diclofen | Diclofenac | Dicloflam | Dicloflame | Diclogen | Diclogin | Diclogold | Diclomax | Diclomol | Diclomove | Diclonac | Diclonat-tr | Diclonij | Diclopace | Dicloran | Dicloric | Diclorumatin-mr | Diclostar | Diclot | Diclotal | Dicloter | Diclowin | Dicnac | Dicol | Dicoliv | Dicron | Difen | Difend | Difisal | Dilofen | Dilona | Diran | Divexx | Divon | Divorel | Divorel-k | Dofec | Doflex | Dolex | Dolo-k | Doloact | Dolocide | Dolocide k | Dolosure sr | Dykay | Dynapar | Dynapar aq | Dynapar sr | Dynec | Efetran | Eldofen | Emfen | Esgipyrin ds | Exflam | Famoov | Fen | Fenac | Fenacon | Fenadec | Fenak | Fencure | Fensupp | Flagon | Flanac | Flexyl | Flexyl-k | Fortafen | Frenac | Haloran | Inac | Jonac | Justin | Klofen | Larfen | Lipcy | Lynec | Lysoflam dig | Maxidic | Maxofen | Medinac | Mirafen | Movonac | Nac | Nac sr | Naclo | Nacpot | Neodol | Neodol-k | Neuroflam | Normove | Nudiclo | Nufenac | Ontac | Osteoflam | Oxalgin | Powerflam | Profenac | Reactin | Relaxyl | Remobile | Remobile-k | Rheufen | Rheufen x | Rolod-k | Rumarden | Runac | Scor | Solunac | Sprintex | Subsyde | Supanac | Superaflam | Supra-k | Tromagesic | Tromax | Ultra-k | Unofen-k | Valfen | Vewodina | Vivian | Vivogesic | Volflam sr | Voligesic | Volini | Voliran | Vovcad | Vovecom | Voveran | Vovo | Welnac | Zedonac | Zefort | Zix | Zobid | Zovenac | Zoxin | Zydiclo;
(IQ) Iraq: Diclo | Diclofenac | Diclofenac s awa | Diclofenac sr awa | Furafen | Kindifenac k | Voltex | Voltex k;
(IS) Iceland: Klofen l | Vostar | Vostar R | Vostar-S;
(IT) Italy: Algosenac | Dealgic | Deflamat | Diclofan | Diclofenac | Diclofenac doc | Diclofenac eg | Diclofenac hexal | Diclofenac mylan generics | Diclofenac ratiopharm | Dicloreum | Dicloreum cr | Dicloreum dolore | Fenadol | Fender | Flectorgo | Flogofenac | Forgenac | Itamifast | Lisiflen | Novapirina | Safidol | Voltadvance | Voltaren | Voltfast;
(JO) Jordan: Almiral | Cataflam | Clofen | Diclofen | Diclogesic | Diclomax | Diclosal | Diclotab | Diclover | Difen | Divido | Dolvic k | Infla ban | Nalgofen | Olfen | Optifen | Rapidus | Rofenac | Rofenac d | Tratul | Voldic | Voldic K | Voltaren | Votrex;
(JP) Japan: Adefuronic jdolph | Adefuronic kayaku | Adefuronic zupo | Adefuronic-L | Anavan | Aspizone | Blesin | Bolabomin | Bolabomin amel | Bolabomin merck hoei | Bolabomin tsuruhara | Buseton | Celtanac | Celtanac choseido | Chlorgy | Daispas | Denbal | Dichronic | Dichrophenon | Diclofe.sod.kob.yk | Diclofe.sod.ohara | Diclofe.sod.yutoku | Diclofenac na nissin | Diclofenac sodium sr ze | Dicsanal | Difenac | Docell | Fenacidon | Fenytaren | Gautelin | Hizemin | Irinatolon | Meclophen | Mericut | Milnac | Naboal | Neriodin merck hoei | Neriodin wakamoto | Nifleriel | Pentiate | Pinanac | Poltajen | Prophenatin | Saffrac | Sannax | Savismin | Seecoren | Shignol | Sofarin | Sorelmon | Strongcoll | Supiaren | Thicataren | Tsudohmin | Verice | Volmagen asahikasei | Volmagen choseido | Volmagen hexal | Volmagen taisho | Voltaren | Vonafec hisamitsu | Vonafec nissin | Vonfenac | Youfenac | Youfenac mita;
(KE) Kenya: Adiflam | Adiflam sr | Almiral | Bionac | Carefenac | Cataflam | Clofen | Clofenac | Clofenac sr | Cosflam | Cosflam sr | D fenac | D pott | Daifen | Deklomol | Diclac | Diclo denk | Dicloas | Diclofen sr | Diclofenac | Diclofenac sodium bp | Diclogen | Diclogen retard | Dicloject | Diclomed | Diclomol | Diclomol sr | Diclopill | Dicloran | Diclosafe | Diclovita | Dicofen | Difisal | Difisal sr | Diflame sr | Dinac | Dinac 100 retard | Dits | Dola cr | Dyclomax | Dyclomax Sr | Dynapar aq | Dynapar ec | Dynapar sr | Elfenac | Fast flam | Fedac sr | Fenac | Flotac | Knac | Lofnac | Medifenac | Mexit | Nasida sr | Nelac | Nudiclo | Olfen | Osteoflam | Penofen | Phlogin | Profenac | Remethan 100 r | Rheumac | Rheumac sr | Rheumarene | Rhumalgan | Rokon | Rufenac | Subsyde | Umeran SR | Velredin | Voltamed | Voltaren | Voltaren retard | Voltaren sr;
(KR) Korea, Republic of: Acitan | Aipexin | Alfenac | Anacen | Athronac | Austaren | Austaren f | Baredan | Betanaxin | Betapen | Betapenac | Borero | Cabinexin | Cadexin | Cafenac | Carufen | Cataflam | Catas | Clentac | Clinfenac | Clodifen | Clofenac | Clonac | Clovana | Cnac | Daihan diclofenac | Depain | Dibeta | Dibeta c | Dicknol | Dicle | Diclo | Diclofenac | Diclofenac guju | Diclofenac sodium injection huons | Diclon | Dicofenac | Dicolon | Difeclo | Difein | Difenac | Diferami | Difexin | Dilonac | Dinacs | Dinopen | Dipeamine | Direxin | Disacten | Dymenic | Emcotin | Esfenac | Febnac | Fenaca | Fenaccan | Fenaclo-beta | Freejex | Globeta | Glofenac | Hana diclofenac sodium | Hawon diclofenac | Hawon diclofenac beta | Hifenac | Impegol | Jeil diclofenac sodium | Jexsta | Kenaksin | Kinpoin | Korus diclofenac | Kyungdong diclofenac | Linac | Lopenac | Lopenak | Mepharen | Merofenac | Mino-v | Monaten | Newbeta | Newfenac | Newvoraren | Orphenac | Os beta | Ows | Painac | Penacle | Progofenac | Pumaron | Retilon | Rolactin | Rotilac | Samjin diclofenac sodium | Sendifen | Sendifen-beta | Sendifen-f | Shinfenac | Shinpoong diclofenac sodium | Sinil Diclofenac Sodium | Sodinac | Sofenac | Tapain | Tapain-beta | Tapenaxin | Tarenac | Toraren | Tyfenac | Unipenak | Valentac | Voltaren | Voraren | Yufenac | Yupain;
(KW) Kuwait: Adwiflam | Cataflam | Clofen | Diclo | Diclo k | Diclo na | Diclofast | Diclogesic | Diclomax | Diclopid | Epifenac | Grofenac | Infla ban | Joflam | Neoflam | Olfen | Rapidus | Rheumarene | Rofenac | Rumafen | Voltaren | Voltic | Votrex;
(LB) Lebanon: Cataflam | Clofen | Cloren | Diclocell | Diclofenac | Diclofenac genericon | Diclogesic | Diclomax | Diclorism | Diclotab | Dikloron | Dilo | Dolmina | Dolonil | Flector | Flogofenac | Flotac | Grofenac | Joflam | Olfen | Primafenac | Rapidus | Remethan | Rofenac | Rofenac d | Tratul | Voldic K | Voltaren | Votrex | Xenid | Zorvolex;
(LT) Lithuania: Almiral | Apo diclo | Betaren | Cataflam | Darvec | Diclac | Diclobene | Dicloberl | Diclofenac | Diclofenac stada | Diclomax | Diclomelan | Diclonac | Diclonat p | Dicloran | Dicuno | Effekton | Feloran | Feloran Uno | Flogofenac | Inflamac | Majamil | Naclofen | Naklofen | Naklofen duo | Olfen | Ortophen | Rewodina | Rheumavek | Sanfinac | Ultrafen | Veral | Voltaren | Voltaren limedika | Xenid;
(LU) Luxembourg: Cataflam | Diclac | Diclofenac eg | Docdiclofe | Motifene | Polyflam | Voltaren;
(LV) Latvia: Almiral | Betaren | Cataflam | Diclac | Diclobene | Dicloberl | Dicloberl n | Diclofenac | Diclofenac rph | Diclofenac stada | Dicloferol | Diclogen | Diclomax | Diclomelan | Diclomol | Diclonac | Diclonat p | Dicloran | Diclorapid | Dicuno | Difisal | Effekton | Feloran | Flogofenac | Inflamac | Majamil | Naklofen | Naklofen duo | Olfen | Ortophen | Profenac | Rewodina | Rheumavek | Sanfinac | Ultrafen | Veral | Voltaren | Voltaren acti | Voltaren resinat | Xenid;
(MA) Morocco: Apo diclofen | Cataflam | Diclo | Dicloberl | Diclofenac win | Diclomax | Dicloreum | Difal | Fenac | No flam | Voltarene | Xenid;
(MT) Malta: Olfen;
(MX) Mexico: Afenilak | Alsidexten | Ariflam | Artrenac | Atalak | Cataflam | Cataflam dd | Cataflam junior | Clo far | Clonafec | Coral | Deflox | Dflam | Dicfafena | Diclac | Diclofen.so.gi | Diclofenac | Diclofenaco | Diclofenaco gi | Diclofenaco gi mav | Diclofenaco gi mer | Diclofenaco kendri | Diclofenaco sodico | Diclogen | Diclopisa | Diprovic | Dirret | Docril | Dofen | Dolflam | Dolflam-retard | Dolo pangavit d | Espitec | Evadol | Fenak | Flamydol | Flotac | Fustaren | Galedol | Genoren | Lertus | Lertus sr | Lifenac | Liroken | Logesic | Mafena | Mafena retard | Manacon | Merxil | Metracin | Nediclon | Ormofen | Practiser | Precifenac | Rotumal | Soldoflam | Volfenac | Volfenac retard | Voltaren | Voltaren dolo | Voltaren retard | Voltaren sr;
(MY) Malaysia: Almiral | Apo diclo | Avonac | Cataflam | Clofec | Clofenac | Diclac | Diclac retard | Diclo | Diclocip | Diclofenac | Diclofenac Siu Guan | Diclogesic | Diclohexal | Diclomol | Dicloran | Dicloren | Diclosian | Diclotroy | Diclowal | Difenac | Difnal | Difnal-k | Dyfenac | Fenac | Fenadium | Fenadium F | Inac | Inflanac | Jonac | Klofen | Lesflam | Naklofen | Neo pyrazon | Olfen | Pritaren | Profenac | Remafen | Remethan | Venac | Vokam | Voltaren | Voren | Votan | Vovo;
(NG) Nigeria: Ac diclo | Acofenac | Al douleurs | Alben diclofenac potassium | Animol | Annoxy | Aramac | Ashfort diclofenac sr | Auscel diclofenac | Ausfnac | B fenac | Bacadic | Befenac | Bentren | Betaren | Betaren 100 sr | Bhp | Bumacaps | Butaflam | Capifen | Chidinick diclofenac sodium | Cinafenac | Clamfenac | Clofenac | Clotafen | Codico | Curefenac | Delidic | Diclofenac | Diclofenac sandoz | Diclogen | Diclokris | Diclosuit | Diclosure | Diclozone | Dimkpain | Dipen | Docteo | Dogofen | Doublemol | Dovefenac | Dozifenac | Edp diclofenac sodium | Edufenac | Felitone diclofenac potassium | Fenal | Frafenac | Glafenac | Gombefenac | Greenfenac | Greenhope diclofenac potassium | Grinflam | Hydiclo | Iykonfenac | Jawadiclo | Jozofenac | Kachanpen | Kinglion diclofenac sodium | Klovac | Klusyl diclofenac | Krishat diclofenac | Kv diclofenac | Labrelax | Labumol | Liricon diclofenac potassium | Lofnac | Macdiclo | Madifency | Marley diclofenac | Masedor | Masterfen | Mayateo diclofenac | Mecure diclofenac | Meem diclofenac potassium | Moriofenac | Mujid diclofenac potassium | Mujid diclofenac sodium | Nasafen | Nci osteifen | Nemedin | Neosteoval | Olfen | Olfen sr | Olphin diclofenac | Ostomed | Otevo | Panac | Panfenac | Pawafenac | Phomnac | Prinogold | Qualifenac | Radiklo | Remflam | Replek diclofenac retard | Rgi diclofenac | Rumaflam | Sadiko | Santufenac | Sd diclofenac potassium | Sivofenac sr | Softhealth diclofenac potassium | Solofenac | Starsteo | Sunymet diclofenac | Sureclofen forte | Tavpal | Tfp diclofenac sodium | Topfenac | Toranac | Tribumol | Tyonex diclofenac potassium | Ulsto fenac | Vistafenac | Voltaren | Votradec | Zemdimol | Zesnac | Zestefenac | Zestefenec | Zikafenac | Zoflam | Zuteo | Zydiclo;
(NL) Netherlands: Cataflam | Diclofenac kalium | Diclofenac kalium actavis | Diclofenac na | Diclofenackalium | Diclofenacnatrium Alpharma | Diclofenacnatrium delphi | Diclofenacnatrium flx | Diclofenacnatrium Merck | Voltaren | Voltaren k;
(NO) Norway: Cataflam | Diclofenac | Diclofenac bluefish | Diclofenac bmm pharma | Diclofenackalium | Dicuno | Ignorin | Modifenac | Otriflu | Voltaren | Voltarol;
(NZ) New Zealand: Apo diclofenac | Cataflam | Diclax | Diclofenac | Diclofenac sandoz | Diclohexal | Flameril | Oraflam | Pharmacy health diclofenac | Voltaren | Voltaren osteo;
(PE) Peru: Acefenac | Anaflex mujer | Apo diclo | Aproxol | Artren | Cataflam | Cordralan | Cordralan R | Deflamat | Diclo k | Diclodor | Diclof | Diclofen | Diclofenac | Diclofenaco | Diclofenaco labot | Diclofenaco sodico | Diclokem | Diclomed | Diclomek | Diphadic long | Divon | Dolfenex | Dolfenex sr | Dolo quimagesico | Dolo tanderil | Dolocordralan | Dolofarmalan | Dolofarmalan fast | Dolofenac | Dololiviolex | Dolopress | Dolotren | Fevran b | Flogene | Flotac | Lavidic long | Motriflam | Olfen | Redex | Syfen sr | Tanderil | Terbofenaco | Volfenac | Voltaren;
(PH) Philippines: Acuflam | Boren | Cataflam | Cataflin | Clofenex | Curafen sr | Diclofam | Diclofenac colestyramine | Diclogen | Diclon | Diclovic | Diclowal | Dictas | Diflac | Diflosid | Disod | Dosanac | Gofenac | Lobafen | Lofenax | Philflam dr | Pyrazon | Ritemed diclofenac sodium | Sitiflam | Subsyde | Vifenac | Voltaren | Voltaren rapid | Vontrafen | Voren | Votan | Zolterol;
(PK) Pakistan: Achedec | Aclonac k | Adfenac | Adfenac p | Adfenac sr | Adik | Adik sr | Aksofenac-k | Alcazar | Almiral | Altoron | Anac | Anaren | Anfenax | Antiflam | Apeflam | Araam | Aramfen | Ardi-k | Arnil | Arnil p | Artecid | Arthopot | Artifen | Artinil k | Artonec | Artonec sr | Astefenac | Avenac | Avorek | Basocap | Beflam | Caflam | Camotaren | Carafenac p | Catafen | Citiflam | Clo tassium | Clodium-K | Clofenac | Clonap | Clop | Cloran-S | Confenac k | Cyclofen | Daiko p | Dardnil | Declam | Dectil | Defenac | Deflam | Dejafin | Delves | Demsun | Demsun p | Denum | Denum k | Denum s | Detaflam | Detran p | Dianic | Dic P | Dic s | Dicast sr | Dicgesic k | Dick | Diclac | Diclo p | Diclo-Heim | Diclodex | Diclofen | Diclofenac | Diclofil | Dicloflam-p | Diclogen | Diclogesic | Diclokalium | Diclolac | Diclomed | Diclonov | Diclopal | Diclopel sr | Dicloran | Dicloras | Diclorep | Dicloscot | Diclosel p | Diclosel s | Diclotab | Diclotim | Diclotram | Diclovat | Diclovel | Diclowal | Diclozaf | Diclozan | Dicmaf | Dicmaf sr | Dicnac p | Dico sr | Dicolive | Dicorum | Dicota | Dicpot | Dicto | Dicto sr | Difen | Difenac | Difisal sr | Difnac | Difold | Difsom | Difsom p | Diklonat p | Dinak | Diosim | Diosim sr | Disney | Dolo-k | Dyclo | Dyclo-p | Dycloxan | Dyna-K | Ephanac | Evofenac | Fapa | Fastaid plus | Fedgesic | Fen-k | Fenac | Fenik-k | Fentolit SR | Fist | Flamatrol | Flamex | Flamsak | Flaren | Forgenac | Frendic | Frendic s | Frodic-P | Glif K | Grofenac | Heltron sr | Hirun | Hirun sr | Hondic | Infast | Inflaban | Inflanac | Jaslokan | Jaslokan sr | Jesnil sr | Jupavolt k | Kafenac | Kaldic | Kalfen | Kaliofenac | Kaydic | Kenac | Kesiflam | Ketagesic | Keygesic | Klic | Klodic | Lofen | Loflam | Lofsim | Lonac | Lopran | Luxafen k | Macdafin | Macdicol | Magnopyrol ds | Matic | Maxit | Mediflam | Megafenac | Mobil K | Moov k | Motaar | Mouflam | Moven | Movonac | Muskel | Nacta | Nadium | Natrium | Neclof | Nepnop | Neurofenac | Newdik | Newfenac | Nfen | Nipgesic | Noltren | Oberon | Odic | Opain | Optel-P | Ostefen | Osti P | Paiko s | Painext | Painext sr | Painnil | Painnil P | Painrest | Panslay | Paplofen p | Penfen | Phlogin | Potanic P | Potran | Puldol | Qrelif | Qufen | Qufen k | Quikrel | Rakafen | Rapiget | Regofenac | Regopyrin | Reho | Reldic | Relsec | Remethan | Rheugin | Rheumatin | Rheumatin k | Rheuyan | Ronset | Rubor | Saifenac | Saifenac sr | Signa | Sintral sr | Sofac | Sofac p | Sonal | Sondic | Spon-K | Stop-P | Swiso | Swiso p | Ticclo sr | U Tran | Ultrafen | Vaclo-pot | Valron | Valron p | Veloft | Veloft sr | Visodic | Volden fort | Voldos | Volfen | Volfenac | Volnac | Voltaflam | Voltec p | Voltral | Voltrex | Voren | Vorenac | Voveron | Vurdon | Welclof | Weldiclof | Xion | Yarnil | Zefam | Zeta fenac k | Ziclofen | Ziclofen s | Ziclopel;
(PL) Poland: Cataflam | Diclac | Diclac duo | Dicloberl | Diclofenac | Diclomax | Dicloratio | Dicloratio retard | Dicloratio uno | Dicloreum | Diclotard | Dicuno | Difadol | Diklofen | Feloran | Flectorgo | Majamil prolongatum | Naklofen | Olfen | Olfen uno | Rewodina | Veral | Voltaren | Voltaren sr;
(PR) Puerto Rico: Cataflam | Diclofenac sodium dr | Diclofenac sodium er | Dyloject | Lofena | Voltaren;
(PT) Portugal: Cataflam | Clofen | Diclof | Diclofenac | Diclofenac mylan | Diclotec | Difnan | Dolacen | Dorcalor | Fenil v | Flameril | Olfen | Painex | Poliartrine | Voltaren;
(PY) Paraguay: Akesis bl | Alarflog | Algiflan | Algiflan lp | Antidol | Antiflex | Beyca flex | Curinflam | Diacevit | Diclofen | Diclofen 100 lp | Diclofen 75 lp | Diclofenac janvier | Diclofenac medicine | Diclofenac potasico imedic | Diclofenac potasico kirei | Diclofenac potasico variquin | Diclofenac sodico landerlan | Diclofenac sodico quimfa | Diclofenac sodico variquin | Diclofenaco genfar | Diclofenaco sodico 50 mg dutriec | Diclofenaco sodico mintlab | Diclogrand | Difenac 100 retard nf | Difenac 75 sr nf | Difenac nf | Difenac rl | Dioxaflex | Dioxaflex cb | Dioxaflex retard | Dolovit | Eca | Eca flex | Efagesic | Flamax | Flamirex | Flexidol | Flexidol retard | Flexiplen | Isoxiflam | Levomin | No dol | Pan reumadil | Pirafen | Pro difenac | Pro flexidol | Relaflex | Rexalgan | Rexfar | Sindrolen | Tonoflex | Vinil | Vinil retard | Voltaren | Voltaren retard | Zorvolex;
(QA) Qatar: Apo-Diclo | Cataflam | Clofast-P | Clofen Julphar | Declophen | Declophen SR | Diclo | Diclo ID | Diclofast | Diclofen | Diclogesic | Diclogesic Children | Diclogesic Retard | Diclopid | Dicloran | Diclowal | Diclowal Retard | Dikloron | Divido | Emifenac | Epifenac | Fast-Flam | Finac SR | Finac SR (EC) | Infla-Ban | Infla-Ban SR | JoFlam | Miyadren | Neoflam | Olfen Dispersible | Olfen-100 SR Depocaps | Olfen-50 Lactab | Olfen-75 | Olfen-75 SR Depotabs | Optifen | Optifen SR | Rapidus | Remethan | Rheumarene | Rodinac | Rofenac | Rofenac SR | Rofenac-D | Rumafen | Tabiflex | Voldic | Voldic SR | Voldic-K | Voltaren | Voltaren D | Voltaren Retard | Voltaren SR | Voltfast | Voltic | Votrex;
(RO) Romania: Almiral | Clafen | Declophen | Diclac | Dicloberl | Diclofen | Diclofenac | Diclofenac arena | Diclofenac duo pharmaswiss | Diclofenac helcor | Diclofenac sodic | Diclogesic | Dicloreum | Epifenac | Feloran | Forgenac | Raplon | Refen | Remethan | Rewodina | Rheumafen | Rheumavek | Voltaren | Voltaren rapid;
(RU) Russian Federation: Almiral | Apo diclo | Bioran | Clofenac | Diclac | Diclobene | Dicloberl | Diclofen | Diclofenac | Diclofenac bufus | Diclofenac fpo | Diclofenac mff | Diclofenac ratiopharm | Diclofenac reneval | Diclofenac retard obolenskoje | Diclofenac sandoz | Diclofenac velfarm | Diclogen | Diclogesic | Diclomax | Diclomelan | Diclonac | Diclonat p | Dicloran | Diclorium | Diclovit | Flotac | Flotak | Forgenac | Naklofen | Naklofen duo | Naklofen sr | Neodol | Olfen | Ortofen | Ortofer | Ortophen | Rapten | Rapten duo | Rewodina | Sanfinac | Swissjet duo | Tabuk di | Umeran | Veral | Voltaren | Voltaren acti | Voltaren rapid | Votrex | Xenid;
(SA) Saudi Arabia: Apo diclo | Cataflam | Clofast p | Clofen | Diclac | Diclogesic | Diclomax | Diclopid | Diclorism | Dolvic k | Fast flam | Infla ban | Joflam | Oflam | Olfen | Rapidus | Rheumarene | Rofenac | Rumafen | Tabiflex | Voltaren | Votrex;
(SE) Sweden: Diclofenac bmm pharma | Diclofenac ratiopharm | Diclofenac T ratiopharm | Dicuno | Diklofenak Copyfarm | Diklofenak merck nm | Diklofenak mylan | Diklofenak nm pharma | Diklofenak orifarm | Diklofenak sandoz | Diklofenak t abece | Diklofenak T Actavis | Diklofenak t apofri | Diklofenak T Copyfarm | Diklofenak T Evolan | Eeze | Eezeneo | Ignorin | Voltaren | Voltaren t;
(SG) Singapore: Almiral | Apo diclo | Cataflam | Clofec | Diclo | Diclo denk | Diclofenac | Dicloreum | Diclowal | Difenac | Difnal | Dosanac | Fenac | Fenadium | Flogofenac | Inac | Inflanac | Neodol 50 | Olfen | Pritaren | Remafen | Remethan | Voltaren | Voren;
(SI) Slovenia: Dicuno | Naklofen | Naklofen duo | Olfen | Voltaren;
(SK) Slovakia: Almiral | Diclac | Diclobene | Diclofenac | Diclofenac al | Diclofenac duo | Dicloreum | Dicuno | Dolmina | Flector ep | Inflamac | Olfen | Rewodina | Veral | Voltaren | Voltaren actigo;
(SL) Sierra Leone: Dibumol | Dili | Lofnac | Miral diclofenac | Ronfenac | Voltika | Welcofen;
(TH) Thailand: Almiral | Antiren-f | Artharen | Cataflam | Catanac | Chai fenac | Clonac | Diclo sr | Diclofen | Diclofenac | Dicloflex | Diclogesic | Diclomac | Diclonac | Diclopain | Dicomed | Difenac | Dinac | Doflam | Donac | Dynapar aq | Fenac | Fenacstar | Flogofenac | Inflanac | Klyzen | Myogit | N zen | Neofenac | Neritan | Olfen | Olfenac | Ostaren | Pipfenac | Remethan | Staren | Vesconac | Vivian | Volclonac r | Volfen | Volfenac | Volta | Voltanac | Voltaren | Voren | Votamed | Vtop s;
(TN) Tunisia: Dicloberl | Diclofen | Diclogesic | Diclopal | Dicloreum | Forgenac | Voltarene | Votrex | Xedol | Xenid;
(TR) Turkey: Cataflam | Deflamat | Dicloflam | Diclomec | Difenak | Difenject | Diflodol | Dikloron | Dikloron sr | Dolorex | Feoptidin | Kalidren | Miyadren | Rapidus | Rodinac | Turktipsan Diklofenak sodyum | Volfenaks | Voltaren;
(TW) Taiwan: Adefuronic | Almiral | Batafil | Blesin | Bolabomin | Boltonin | Cataflam | Clofen | Clofen P | Coyenpin | Deflam-K | Diclo denk | Diclof | Diclofen | Diclofenac | Diclofon | Diclomelan | Diclophen | Dicloton | Dicok | Difen | Difenac | Diltaren | Ellic | Fenytaren | Flamquit | Formin | Grofenac | Lidonin "tai yu" | Meitifen | Neriodin | Olfen | Peiflam | Prophenatin | Psutarin | Remethan | Roitonin | Shoren tf | Sorelmon | Staren | Sumofen e.c. | Tsudohmin | Venton | Volna-k | Voltaren | Voren | Voren-k;
(UA) Ukraine: Almiral | Argett duo | Bioran | Clodifen | Diclac | Diclobene | Dicloberl | Dicloberl retard | Diclobru | Diclodev | Diclofen | Diclofenac | Diclogen | Diclomax | Diclonac | Dicloran | Diclosafe | Diclotard | Diclovit | Dolox retard | Feloran | Naklofen | Naklofen duo | Olfen | Olfen lactab | Ortofen forte | Ortophen | Ortophenum forte | Rapten | Rapten retard | Rewodina | Rheumavek | Sanfinac | Veral | Volfenac | Voltaren;
(UG) Uganda: Adiflam | Adwiflam | Agodic | Agonac | Artimed | Cataflam | Clofenac | Clofenac sr | Diclo denk | Diclo denk 100 retard | Dicloas | Diclodyne | Diclomol | Diclomol sr | Dicloran | Dicloren | Difenac | Dinasod | Fensupp | Knac | Lufenac | Maxit | Olfen | Pinnadip | Umeran SR | Voltaren | Voltaren sr | Voren;
(UY) Uruguay: Algilem | Aliviol | Befol | Cataflam | Diclofenac | Diclopharm | Dioxaflex | Flogene | Flogosin | Flogosin s | Flotac | Oxa | Supel | Voltaren | Xedenol | Yargon;
(VE) Venezuela, Bolivarian Republic of: Aflamax | Artren | Bioflenac | Campal | Cataflam | Clofen | Diclodex | Diclofen P | Diclofenac | Diclofenac k | Diclofenac potasico | Diclofenac sodico | Diclofenaco | Diclofenaco potasico | Diclofenaco sodico | Diclofevin | Diclomedc | Difenac | Dikaspen | Diklason | Disodex | Dival | Dival forte | Dolcan | Dotron | Fexicaps | Flamydol | Flotac | Geldenak | Klafenac | Lofnac | Ofaflan | Poltax | Valdipot | Viavox | Voltaren;
(VN) Viet Nam: Elaria | Fenagi | Lofnac | Mekofenac | Richfenac | Stadlofen;
(ZA) South Africa: Acu-diclofenac | Adco diclofenac | Apo diclofenac | Arcanafenac | Austell diclofenac | Cataflam | Clofelam | Diclofenac biotech | Diclofenac oethmaan | Dicloflam | Diclohexal | Difen | Dynak | Flexagen | Fortfen | K fenak | Micro diclofenac | Motifine | Mylan diclofenac | Panamor | Veltex | Voltaren | Voltaren acti go;
(ZM) Zambia: Adiflam | Adiflam sr | Agonac | Ar diclo | Balnac | Cataflam | Clofen | Clofenac | Clofenac sr | Decifen | Defnil | Dflam | Dicinac | Diclo denk | Diclofenac | Diclofil | Dicloflame | Diclogen | Diclokant | Diclomove | Diclonac | Difisal | Dinac | Doloact | Dolphin | Dynapar aq | Dynapar sr | Flagon | Flotac | Knac | Lydic | Panamor | Profenac | Remethan | Rufenac | Subsyde | Umeran | Voltaren | Voltfast | Voltika | Zobid;
(ZW) Zimbabwe: Almiral | Bioran | Cataflam | Diclofenac | Panamor | Panamor at | Remethan | Vivian | Voltaren

2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122(24):2619-2633. doi:10.1161/CIR.0b013e318202f701 [PubMed 21060077]
Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-1039. doi:10.1111/head.14153 [PubMed 34160823]
American College of Obstetricians and Gynecologists (ACOG). ACOG committee on clinical practice guidelines–obstetrics. Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. Obstet Gynecol. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766 [PubMed 35576364]
American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 209: Obstetric analgesia and anesthesia. Obstet Gynecol. 2019;133(3):e208-e225. doi:10.1097/AOG.0000000000003132 [PubMed 30801474]
Baker M, Perazella MA. NSAIDs in CKD: are they safe? Am J Kidney Dis. 2020;76(4):546-557. doi:10.1053/j.ajkd.2020.03.023 [PubMed 32479922]
Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Curr Opin Rheumatol. 2014;26(3):334-340. doi:10.1097/BOR.0000000000000054 [PubMed 24663106]
Bhangu A, Singh P, Fitzgerald JE, Slesser A, Tekkis P. Postoperative nonsteroidal anti-inflammatory drugs and risk of anastomotic leak: meta-analysis of clinical and experimental studies. World J Surg. 2014;38(9):2247-2257. doi:10.1007/s00268-014-2531-1 [PubMed 24682313]
Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502-1517. [PubMed 19017521]
Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884 [PubMed 33942342]
Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013;116(5):1063-1075. doi:10.1213/ANE.0b013e31828a4b54 [PubMed 23558845]
Cambia (diclofenac) [prescribing information]. Lake Forest, IL: Assertio Therapeutics, Inc; April 2021.
Cambia (diclofenac) [prescribing information]. Newark, CA: Depomed; September 2019.
Cambia (diclofenac) [product monograph]. Mississauga, Ontario, Canada: Aralez Pharmaceuticals Canada Inc; December 2021.
Cataflam (diclofenac) [prescribing information]. East Hanover, NJ: Novartis; April 2021.
Cheng TT, Lai HM, Chiu CK, Chem YC. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther. 2004;26(3):399-406. doi:10.1016/s0149-2918(04)90035-5 [PubMed 15110132]
Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131-157. doi:10.1016/j.jpain.2015.12.008 [PubMed 26827847]
Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. Eur J Clin Pharmacol. 2019;75(10):1347-1353. doi:10.1007/s00228-019-02712-2 [PubMed 31273431]
Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. doi:10.2337/dci18-0033 [PubMed 30291106]
Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;2013(4):CD008783. doi:10.1002/14651858.CD008783.pub3 [PubMed 23633360]
The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia. 1999;19(4):232-240. doi:10.1046/j.1468-2982.1999.019004232.x [PubMed 10376168]
Diclofenac potassium tablets [prescribing information]. Fairmont, WV: INA Pharmaceuticals Inc; September 2021.
Diclofenac sodium delayed-release tablets [prescribing information]. Columbus, OH: American Health Packaging; April 2021.
Diclofenac sodium extended-release tablets [prescribing information]. Bridgewater, NJ: Oceanside Pharmaceuticals; November 2020.
Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi: 10.1002/acr.24180 [PubMed 32391934]
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061. [PubMed 26934393]
Gaffo AL. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 9, 2023.
Gurwitz JH, Avorn J, Ross-Degnan D, et al, “Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,” JAMA, 1990, 264(4):471-5. [PubMed 2366280]
Haapasaari J, Wuolijoki E, and Ylijoki H, “Treatment of Juvenile Rheumatoid Arthritis With Diclofenac Sodium,” Scand J Rheumatol, 1983, 12(4):325-30. [PubMed 6361986]
Health Canada. Summary safety review - diclofenac - risk of major heart and stroke related adverse events. http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/diclofenac-eng.php. Published October 6, 2014. Updated October 14, 2014. Accessed September 25, 2017.
Horsley RD, Vogels ED, McField DAP, et al. Multimodal postoperative pain control is effective and reduces opioid use after laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2019;29(2):394-400. doi: 10.1007/s11695-018-3526-z. [PubMed 30317488]
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013;3(suppl):1-150.
Leak AM, Richter MR, Clemens LE, Hall MA, Ansell BM. A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin Exp Rheumatol. 1988;6(2):157-160. [PubMed 3052965]
Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;2015(7):CD001751. doi:10.1002/14651858.CD001751.pub3 [PubMed 26224322]
Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. Breastfeed Med. 2018;13(3):164-171. doi:10.1089/bfm.2018.29087.ejm [PubMed 29595994]
McVige JW, Hogan RM, Shanahan CM, Amend DL, Ferger SM. An open-label study evaluating the pharmacokinetics and safety of diclofenac potassium for oral solution for the acute treatment of MWA or MWoA in pediatric participants. Headache. 2020;60(9):1939-1946. doi: 10.1111/head.13922 [PubMed 32767766]
Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025 [PubMed 31917200]
Petty RE, Laxer RM, Lindsley CB, Wedderburn LR. Textbook of Pediatric Rheumatology. 7th ed. Elsevier; 2016.
Phillips K, Schur PH. Management of isolated musculoskeletal chest pain. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 19, 2021.
Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. Breastfeed Med. 2017;12(9):500-506. [PubMed 29624435]
Refer to the manufacturer's labeling.
Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651-1653. doi:10.1002/hep.26359 [PubMed 23463403]
Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529‐556. doi:10.1002/art.41191 [PubMed 32090480]
Schwedt TJ, Garza I. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 12, 2021.
Stierlin H, Faigle JW, Colombi A. Pharmacokinetics of diclofenac sodium (Voltaren) and metabolites in patients with impaired renal function. Scand J Rheumatol Suppl. 1978;(22):30-35. doi:10.3109/03009747809097213 [PubMed 356243]
Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol. 2016;111(4):459-474. doi:10.1038/ajg.2016.41 [PubMed 26925883]
Thorell A, MacCormick AD, Awad S, et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. World J Surg. 2016;40(9):2065-2083. doi:10.1007/s00268-016-3492-3 [PubMed 26943657]
US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory.
US Food and Drug Administration (FDA). FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic. Published October 15, 2020. Accessed October 20, 2020.
van Tubergen A. Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 19, 2021.
Voltaren (diclofenac) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; June 2016.
Voltaren (diclofenac) [product monograph]. Macquarie Park, New South Wales, Australia: Novartis Pharmaceuticals Australia Pty Limited; October 2019.
Voltaren Rapide (diclofenac) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; October 2021.
Voltaren SR (diclofenac) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; July 2018.
Voltaren, Voltaren SR (diclofenac) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; June 2022.
Voltaren, Voltaren SR (diclofenac) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; October 2019.
Voltaren-XR extended-release tablets (diclofenac) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2021.
Voltarol Suppositories (diclofenac) [summary of product characteristics]. Surrey, United Kingdom: Novartis Pharmaceuticals UK Ltd; March 2017.
Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013;40(5)(suppl 3):S1-S80. [PubMed 23968886]
Zhang YK, Yang H, Zhang JY, Song LJ, Fan YC. Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. Int J Clin Pract. 2014;68(5):633-638. doi:10.1111/ijcp.12359 [PubMed 24472084]
Zipsor (diclofenac) [prescribing information]. Lake Forest, IL: Assertio Therapeutics Inc; May 2021.
Zorvolex (diclofenac) [prescribing information]. Wayne, PA: Zyla Life Sciences US Inc; April 2021.

Topic 9103 Version 791.0

خرید پکیج

Diclofenac (systemic): Drug information